A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients
スポンサーリンク
概要
- 論文の詳細を見る
- 2010-10-10
著者
-
岡部 尚文
日本ロシュ研究所
-
Okabe H
Hanno Research Center Taiho Pharmaceutical Co. Ltd.
-
岡部 尚文
日本ロシュ(株)研究所抗癌剤研究部
-
Yamada‐okabe H
Department Of Oncology Nippon Roche Research Center
-
Yamada Okabe
Pharmaceutical Research Department Chugai Pharmaceutical
-
Yamada Okabe
Pharmaceutical Research Department Iii Kamakura Research Laboratories
-
Yamada-okabe Hisafumi
Department Of Mycology Nippon Roche Research Center
-
Yamada-okabe Hisafumi
Dept. Of Mycology Nippon Roche Reserch Center
-
Ozaki S
Department Of Medicine And Bioregulatory Sciences Institute Of Health Biosciences The University Of
-
Kawai Shigeto
Pharmaceutical Research Department Chugai Pharmaceutical
-
岡部 尚文
中外製薬(株)創薬企画推進部
-
Ozaki Shuji
Department Of Medicine And Bioregulatory Sciences Institute Of Health Biosciences The University Of
-
Kawai Shigeto
Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
-
ISHIGURO Takahiro
Pharmaceutical Research Department 3, Chugai Pharmaceutical Co. Ltd
-
HABU Kiyoshi
Genome Antibody Product Research Department, Chugai Pharmaceutical Co. Ltd
-
SUGIMOTO Masamichi
Pharmaceutical Research Department 3, Chugai Pharmaceutical Co. Ltd
-
SHIRAIWA Hirotake
Genome Antibody Product Research Department, Chugai Pharmaceutical Co. Ltd
-
IIJIMA Shigeyuki
Genome Antibody Product Research Department, Chugai Pharmaceutical Co. Ltd
-
OZAKI Shuji
Tokushima University
-
MATSUMOTO Toshio
Tokushima University
-
YAMADA OKABE
Research Planning and Coordination Department, Chugai Pharmaceutical Co. Ltd
-
Yamada Okabe
Research Planning And Coordination Department Chugai Pharmaceutical Co. Ltd
-
Iijima Shigeyuki
Genome Antibody Product Research Department Chugai Pharmaceutical Co. Ltd
-
Shiraiwa Hirotake
Genome Antibody Product Research Department Chugai Pharmaceutical Co. Ltd
-
Ishiguro Takahiro
Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
-
Sugimoto Masamichi
Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
-
Habu Kiyoshi
Genome Antibody Product Research Department Chugai Pharmaceutical Co. Ltd
-
Matsumoto Toshio
Department Of Medicine And Bioregulatory Sciences Institute Of Health Biosciences The University Of
-
Yamada-Okabe Hisafumi
Research Planning and Coordination Department, Chugai Pharmaceutical Co. Ltd
関連論文
- PP-1-293 通常型膵癌非治癒因子に関する臨床病理学的および分子生物学的検討
- Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray
- Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5-Fluorouracil
- Effects of Iprodione and Fludioxonil on Glycerol Synthesis and Hyphal Development in Candida albicans(Microbiology & Fermentation Technology)
- Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma
- Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models
- Saccharomyces cerevisiae キチン合成酵素の発現機構の解析 : 微生物
- S.cerevisiaeキチン合成酵素2の大量発現と部分精製 : 酵素
- DPE-065 A Combination of Erythropoietin Administration with Autologous Blood Donation for Therapeutic Angiogenesis(DPE11,Kidney/Renal Circulation/CKD (H),Digital Poster Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Socie
- Relationship between Protein Levels and Gene Expression of Dihydropyrimidine Dehydrogenase in Human Tumor Cells during Growth in Culture and in Nude Mice
- Involvement of cyclooxygenase-2 in the tumor site-dependent production of parathyroid hormone-related protein in colon 26 carcinoma
- Sensitivity, of Human Cancer Cells to the New Anticancer Ribo-nucleoside TAS-106 Is Correlated with Expression of Uridine-cytidine Kinase 2
- Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma
- 抗体医薬の現状と展望
- Genomics を用いた創薬研究 : 新規標的分子の探索, High-throughput screening, 及び診断への応用(植物保護とバイオテクノロジー : バイオテクノロジー技術の農薬研究への応用)
- SI5 Genomics を用いた創薬研究 : 新規標的分子の探索、 high-throughput screening 及び診断への応用
- The gene cloning and characterization of 1, 3-β-glucan synthase from Candida albicans
- Charaterization of Chitin Synthase 2 of Saccharomyces cerevisiae II: Both Full Size and Processed Enzymes Are Active for Chitin Synthesis
- Primary Adult T-Cell Leukemia/Lymphoma of Bone
- Biclonal Lymphoplasmacytic Immunocytoma Associated with Crohn's Disease
- A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients
- Multiple myeloma : new aspects of biologtyand treatment
- A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway
- Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells
- Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma
- 酵母のキチン合成酵素の機能と性質
- Type 2B-like acquired von Willebrand syndrome
- Characterization of Chitin Synthase 2 of Saccharomyces cerevisiae II: Both Full Size and Processed Enzymes Are Active for Chitin Synthesis.